Request Demo
Asahi Kasei scoops up Germany\'s Aicuris for $920M in R&D portfolio boost
Clinical ResultDrug ApprovalAcquisitionPhase 3License out/in
Asahi Kasei's move to acquire Aicuris will give it access to candidates in Aicuris’ pipeline, including a herpes simplex therapy that generated positive phase 3 results.
Asahi Kasei has unveiled plansAicurisuire Aicuris in a deal worth 780 milliAicuriss ($920 million), marking the latest in a series of biotech M&A deals in recent weeks.
Asahi Kaseithe deal enables the Japanese cAicurisrate to add several approved and investigational assets designed to treat and protect against viral infections in immunocompromised individuals.
AsahAsahi.S. subsidiary Veloxis Pharmaceuticals will execute the acquisition of Germany’s Aicuris, growing Asahi’s R&D portfolio by adding candviral infectionsto treat patients experiencing complications connected to hematopoietic stem cell transplants, solid organ transplants and other immunologically driven conditions, according to the Feb. 26 release.
Asahiis spun out of BayeVeloxis Pharmaceuticals, had raised $75 million to focus on antiviral and antibacteAsahicompounds. In 2012, Aicuris entered into an agreement with Merck to bring its flagship transplant infection prevention product, Prevymis, to market.
AsahFDA move will also give it access to candidaMerckn Aicuris’ pipeline, including a herpes simplex therapy that has generated positive phase 3 results and a phase 2-ready antiviral for kidney transplant patients to protect them from the “potentially severe consequence” of BK virus, according to the release.
The Aicurisrks the second acquisition by Asahi in less than two years after it made a billion-dollar offer for Sweden's Calliditas Therapeutics in Asahi Kaseihich followed the FDA approval of Calliditas' immunoglobulin A nephropathy treatment. Asahi also strengthened its antibody manufacturing capabilities by acquiring CDMO Bionova in 2022.
And, just yesterday, Asahi announced a glAsahilicense agreement with small-molecule drug specialist Alchemedicine to bolCalliditas Therapeuticsvery pipeline.FDAimmunoglobulin A nephropathyAsahi
As for the Aicuris buAsahi the acquisition stands to accelerate the biotech's research and launch reAlchemedicinee U.S. whileAsahinding the reach of the company’s therapies for immunocompromised patients, CEO Larry Edwards said in a statement.
The Asehi KAicurisansaction is expected to close in the first half of this year.
Elsewhere, the biotech M&A scene has come alive lately, with GSK this week paying $950 million for Canadian biotech 35Pharma. In addition, just this month, Gilead Sciences forked over $7.8 billion for its CAR-T partner Arcellx, and Eli Lilly spent $2.4 billion on Orna Therapeutics.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!